These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35183108)

  • 1. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD.
    Click B; Barnes EL; Cohen BL; Sands BE; Hanson JS; Rubin DT; Dubinsky MC; Regueiro M; Gazis D; Crawford JM; Long MD
    BMC Gastroenterol; 2022 Feb; 22(1):71. PubMed ID: 35183108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
    Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
    J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Objective Therapeutic Monitoring and Outcomes in Patients with Inflammatory Bowel Disease with Adalimumab Treatment. A Real-world Prospective Study.
    Wetwittayakhlang P; Golovics PA; Khoury AA; Ganni E; Hahn GD; Cohen A; Wyse J; Bradette M; Bessissow T; Afif W; Wild G; Bitton A; Lakatos PL
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):403-410. PubMed ID: 36535055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort.
    Al Khoury A; Xiao Y; Golovics PA; Kohen R; Afif W; Wild G; Friedman G; Galiatsatos P; Hilzenrat N; Szilagyi A; Wyse J; Cohen A; Bitton A; Bessissow T; Lakatos PL
    Dig Liver Dis; 2021 Aug; 53(8):980-986. PubMed ID: 33640302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
    Kaplan JL; Liu C; King EC; Bass JA; Patel AS; Tung J; Chen S; Lissoos T; Candela N; Saeed S; Colletti RB;
    J Pediatr Gastroenterol Nutr; 2023 May; 76(5):566-575. PubMed ID: 36804501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
    Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
    BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort.
    Azzam N; Aljebreen A; Alharbi O; Charabaty A; Alanazi M; Alkuwaykibi N; Alfaraidi J; Bashamil A; Almansour T; Almadi M
    Arab J Gastroenterol; 2021 Mar; 22(1):66-72. PubMed ID: 33632623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease.
    Limketkai BN; Singh S; Jairath V; Sandborn WJ; Dulai PS
    Inflamm Bowel Dis; 2019 Oct; 25(11):1828-1837. PubMed ID: 31039246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
    Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study.
    Anisdahl K; Svatun Lirhus S; Medhus AW; Moum B; Melberg HO; Høivik ML
    Scand J Gastroenterol; 2021 Oct; 56(10):1163-1168. PubMed ID: 34320885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Declining Rates of Surgery for Inflammatory Bowel Disease in the Era of Biologic Therapy.
    Lowe SC; Sauk JS; Limketkai BN; Kwaan MR
    J Gastrointest Surg; 2021 Jan; 25(1):211-219. PubMed ID: 33140318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil.
    Zaltman C; Parra RS; Sassaki LY; Santana GO; Ferrari MLA; Miszputen SJ; Amarante HMBS; Kaiser Junior RL; Flores C; Catapani WR; Parente JML; Bafutto M; Ramos O; Gonçalves CD; Guimaraes IM; da Rocha JJR; Feitosa MR; Feres O; Saad-Hossne R; Penna FGC; Cunha PFS; Gomes TN; Nones RB; Faria MAG; Parente MPPD; Scotton AS; Caratin RF; Senra J; Chebli JM
    World J Gastroenterol; 2021 Jan; 27(2):208-223. PubMed ID: 33510560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.